Abstract 773P
Background
Homologous Recombination Deficiency (HRD) is assessed by detection of mutations in BRCA1/2 genes (BRCAm) and/or genomic instability score (GIS+). In ovarian cancer, HRD has become an important biomarker to stratify patients for appropriate clinical management and treatment. Myriad myChoice CDX Plus is currently the gold standard for assessing HRD on tumor samples. There is an increasing interest in transitioning into inhouse HRD assays that fulfill analytical concordance and, also, demonstrate clinical validation. Sophia DDM Dx HRD solution is one of the alternatives, which has reached an overall percent agreement of 93% with Myriad, demonstrating also clinical validation in PAOLA-1 trial. In this study, we present the real-world results of HRD testing in Spain.
Methods
Phase 1 (Apr2021-Jun22), consisted in the analysis of 1322 cases from 90 centers, using Myriad myChoice. Phase 2 (Jul2022-Dec22) included 1333 cases from 135 centers, analyzed with Sophia HRD solution in 4 academic centers, after an internal validation.
Results
Phase 1 reported 47% BRCAwt/GIS-, 24% BRCAwt/GIS+, 14% BRCAm (BRCAm/GIS- y BRCAm/GIS+), and 15% inconclusive cases using myChoice. In phase 2, Sophia HRD identified 47% BRCAwt GIS-, 25% BRCAwt/GIS+, 15% BRCAm, and 13% inconclusive cases. The distribution of HRP (range 42.4-50%) and HRD (range 35.7- 40.7%) cases was similar among the reference centers. In addition to GIS and BRCA1/2, Sophia reported CCNE1 amplification (5.3%), as well as mutations in BRIP1 (2.4%), RAD51C (1.1%), RAD51D (1.2%) and PALB2 (1.9%). As expected, CCNE1 amplification was more frequent in HRP (86.5%) than HRD (13.5%).
Conclusions
The results obtained from a cohort of 2655 ovarian cancer samples by two different methods, Myriad myChoice and Sophia HRD, confirm the analytical concordance between HRD assays. Percentages of BRCAwt/GIS-, BRCAwt/GIS+, BRCAm, and invalid cases were almost identical. In conclusion, Sophia DDMTM Dx HRD solution shows a high interlaboratory agreement, providing clinically relevant molecular information, and improving the interaction between referral and reference centers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Federico Rojo.
Funding
AstraZeneca.
Disclosure
M. Orellana: Financial Interests, Personal, Member: AstraZeneca. M. Lencina: Financial Interests, Personal, Other: AstraZeneca. X. Matias-Guiu: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Lilly, GSK, Janssen; Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK, Clovis; Non-Financial Interests, Other, Consultancy: AstraZeneca. F. Rojo: Financial Interests, Personal, Advisory Board: Roche, MSD, BMS, Novartis, AstraZeneca, Daiichi Sankyo, GSK; Financial Interests, Personal, Invited Speaker: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
812P - Mental and socioeconomic burden in co-parents and children of patients with endometrial and cervical cancer: A Swedish population-based study
Presenter: Karin Sundström
Session: Poster session 11
814P - Clinical significance of isolated pulmonary recurrence in patients with endometrioid endometrial cancer who achieved complete remission after primary treatment
Presenter: Jigeun Yoo
Session: Poster session 11
815P - Clinical outcome of metastatic endometrial carcinoma patients treated with chemotherapy: ENDOVIE, a GINECO national observational cohort study
Presenter: Jerome Alexandre
Session: Poster session 11
816P - Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
Presenter: Alain Zeimet
Session: Poster session 11
817P - A systematic review of recruitment of ethnic minorities to RCTs of systemic anti-cancer therapies in gynaecological cancers
Presenter: Luke Steventon
Session: Poster session 11